Hepatotropic medicines: current status


Cite item

Full Text

Abstract

Limits of administration, efficacy and safety of hepatotropic drugs are not finally formulated yet because of lack of clinical trials which satisfy current principles of evidence-based medicine. The review analyses data on clinical use of drugs for which hepatotropic action is leading, prevalent or clinically independent; gives information on composition of some drugs, pharmacodynamics, pharmacokinetics, principles of clinical administration, side effects, clinical trials; outlines a mechanism of action and area of application of a new original hepatotropic drug remaxol. Experimental data are available on remaxol ability to reduce hepatic affection induced by hepatotoxic agents and severity of carbohydrate, protein and fat dystrophy, to activate regeneration of the liver. Clinical trials demonstrate remaxol efficacy in management of toxemia, cytolysis, cholestasis. The above effectiveness and its antiasthenic and antidepressive activity makes this drug a universal hepatotropic medicine effective in various hepatic diseases (viral hepatitis C, toxic and pharmacological damage) both in therapeutic and prophylactic schemes.

About the authors

Sergey Vladimirovich Okovityy

Email: okovityy@mail.ru

Dmitriy Sergeevich Sukhanov

A Yu Petrov

Mikhail Grigor'evich Romantsov

S V Okovity

S.M. Kirov Military Medical Academy, St-Petersburg

S.M. Kirov Military Medical Academy, St-Petersburg

D S Sukhanov

I.I. Mechnikov North-west medical university, St-Petersburg

I.I. Mechnikov North-west medical university, St-Petersburg

A Yu Petrov

M G Romantsov

I.I. Mechnikov North-west medical university, St-Petersburg

I.I. Mechnikov North-west medical university, St-Petersburg

References

  1. Kuntz E., Kuntz H.-D. Hepatology. Principles and practice. Wetzlar: Springer; 2006.
  2. Muriel P., Rivera-Espinoza Y. Beneficial drugs for liver diseases. J. Appl. Toxicol. 2008; 28: 93-103.
  3. Schmidt R. Hepatic organ protection: from basic science to clinical practice. Wld J. Gastroenterol. 2010; 16: 6044-6045.
  4. Оковитый С. В., Безбородкина Н. Н., Улейчик С. Г., Шуленин С. Н. Гепатопротекторы. М.: ГЭОТАР-Медиа; 2010.
  5. Chien C. F., Wu Y. T., Tsai T. H. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed. Chromatogr. 2011; 25: 21-38.
  6. Sun B., Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008; 27: 6228-6244.
  7. Dhiman R. K., Chawla Y. K. Herbal medicines for liver diseases. Dig. Dis. Sci. 2005; 50: 1807-1812.
  8. Post-White J., Ladas E. J., Kelly K. M. Advances in the use of milk thistle (Silybum marianum). Integr. Cancer Ther. 2007; 6: 104-109.
  9. Negi A. S., Kumar J. K., Luqman S. et al. Recent advances in plant hepato-protectives: a chemical and biological profile of some important leads. Med. Res. Rev. 2008; 28: 746-772.
  10. Verma S., Thuluvath P. J. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin. Gastroenterol. Hepatol. 2007; 5: 408-416.
  11. Falaska K., Ucciferri C., Mancino P. et al. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J. Med. Virol. 2008; 80: 1900-1906.
  12. Pittler M. H., Thompson C. J., Ernst E. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst. Rev. 2002; Issue 3: Art. № CD003335. doi: 10.1002/14651858.CD003335.
  13. Mitra S. K., Varma S. R,., Godavarti A., Nandakumar K. S. Liv.52 regulates ethanol induced PPARgamma and TNF alpha expression in HepG2 cells. Mol. Cell. Biochem. 2008; 315: 9-15.
  14. Huseini H. F., Alavian S. M., Heshmat R. et al. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine 2005; 12: 619-624.
  15. Kolhapure S. A., Mitra S. K. Meta-analysis of phase III clinical trials in evaluation of efficacy and safety of Liv-52 in infective hepatitis. Med. Update 2004; 12: 51-61.
  16. Иванченкова Р. А., Гаценко В. П., Атькова Е. Р. Энтеросан и гепатосан в лечении диспепсии при хронических заболеваниях желчевыводящих путей. Поликлиника 2009; 2: 48-50.
  17. Ушкалова Е. А. Место эссенциальных фосфолипидов в современной медицине. Фарматека 2003; 10: 40-46.
  18. Ивашкин В. Т. (ред.). Рациональная фармакотерапия заболеваний органов пищеварения: руководство для практикующих врачей. M.: Литтера; 2003.
  19. Никитин И. Г. Гепатопротекторы: мифы и реальные возможности. Фарматека 2007; 13: 14-18.
  20. Asl M. N., Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother. Res. 2008; 22: 709-724.
  21. Orient H., Hansen B. E., Willems M. et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J. Hepatol. 2006; 45: 539-546.
  22. Shiraki K., Takei Y. General therapy of type C chronic hepatitis: efficacy and limitation of hepatoprotective agents. Nippon Naika Gakkai Zasshi 2008; 97: 28-35.
  23. Rossum T. G. van, Vulto A. G., de Man R. A. et al. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment. Pharmacol. Ther. 1998; 12: 199-205.
  24. Надинская М. Ю. Печеночная энцефалопатия. В кн.: Ивашкин В. Т. (ред.). Болезни печени и желчевыводящих путей: руководство для врачей. М: Изд. дом "М-Вести"; 2005. 278-290.
  25. Morgan M. Y., Blei A., Grungreiff K. et al. The treatment of hepatic encephalopathy. Metab. Brain Dis. 2007; 22: 389-405.
  26. Foster K. J., Lin S., Turck C. J. Current and emerging strategies for treating hepatic encephalopathy. Crit. Care Nurs. Clin. N. Am. 2010; 22: 341-350.
  27. Als-Nielsen B., Gluud L. L., Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst. Rev. 2004; Art. № CD003044. doi: 10.1002/14651858.CD003044.pub2.
  28. Mato J. M., Martinez-Chantar M. L., Lu S. C. Methionine metabolism and liver disease. Ann. Rev. Nutr. 2008; 28: 273-293.
  29. Roncaglia N., Locatelli A., Arreghini A. et al. A randomized controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestation cholestasis. Br. J. Obstetr. Gynaecol. 2004; 111: 17-21.
  30. Подымова С. Д. Возможности клинического использования адеметионина у больных с заболеваниями печени. Клин. перспект. гастроэнтерол., гепатол. 2010; 3: 17-24.
  31. Osna N. A. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1 -induced liver injury. Wld J. Gastroenterol. 2010; 16: 1366-1376.
  32. Rambaldi A., Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst. Rev. 2006; Art. № CD002235. doi: 10.1002/14651858.CD002235.pub2.
  33. Samara K., Liu C., Soldevila-Pico C. et al. Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. Dig. Dis. Sci. 2006; 51: 1226-1229.
  34. Суханов Д. С., Виноградова Т. И., Заболотных Н. В. и др. Влияние сукцинатсодержащих препаратов на процессы репаративной регенерации в эксперименте. Хирургия 2011; 1: 56-60.
  35. Оковитый С. В., Гайворонская В. В., Куликов А. Н., Шуленин С. Н. Клиническая фармакология антигипоксантов. В кн.: Избранные лекции по клинической фармакологии. М.: ГЭОТАР-Медиа; 2009. 484-539.
  36. Correa P. R, Kruglov E. A., Thompson-M. et al. Succinate is a paracrine signal for liver damage. J. Hepatol. 2007; 47: 262-269.
  37. Сологуб Т. В., Горячева Л. Г., Суханов Д. С. и др. Гепатопротективная активность ремаксола при хронических поражениях печени (материалы многоцентрового рандомизированного плацебо-контролируемого исследования). Клин. мед. 2010; 1: 62-66.
  38. Шилов В. В., Васильев С. А., Шикалова И. А., Батоцыренов Б. В. Особенности фармакологической коррекции токсической гепатопатии при тяжелых формах острых отравлений алкоголем на фоне длительного злоупотребления ("запоев"). Рус. мед. журн. 2010; 18: 1141-1144.
  39. Суханов Д. С., Виноградова Т. И., Заболотных Н. В. и др. Сравнительное изучение гепатопротективного действия ремаксола, реамберина и адеметионина при повреждении печени противотуберкулёзными препаратами (экспериментальное исследование). Антибиотики и химиотер. 2011; 56 (1-2).
  40. Bru C., Caballeria L., Caballeria J. et al. Metadoxine accelerates fatty liver recovery in alcoholic patients - results of a randomized double-blind, placebo-control trial. J. Hepatol. 1998; 28: 54-60.
  41. Ткач С. М. Эффективность и безопасность гепатопротекторов с точки зрения доказательной медицины. Здоровье Украины 2009; 1: 7-10.
  42. Orlando R., Azzalini L., Orando S., Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 2007; Art. № CD005160.DOI: 110.1002/14651858.CD005160. pub2.
  43. Gong Y., Huang Z. B., Christensen E., Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2008; Art. № CD000551. doi: 10.1002/14651858.CD000551.pub2.
  44. Chen W., Liu J., Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst. Rev. 2007; Art. № CD003181. doi: 10.1002/14651858.CD003181.pub2.
  45. Poropat G., Giljaca V., Stimac D., Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2011; Art. № CD003626. doi: 10.1002/14651858.CD003626.pub2.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies